54 patients had triple negative tumours (30.2%) (Table 2), whereas non-triple negative phenotype defined as the expression of at least one of the three markers (ER, PgR or HER2) was observed in 125 patients (69.8%) (Table 2). This evidence concerns the gene ERBB2 and neoplasm.